Reproduction permitted for personal use only. For reprints and reprint permission, contact email@example.com.
- Medical imaging technology provider GE Healthcare
announced it has begun clinical trials of a new molecular imaging agent for the detection of cancer.
The agent, which uses positron emission tomography (PET), is designed to track the process of angiogenesis, or the formation of new blood vessels in the body. It will be used to quantify therapy for Stage IV metastatic tumors in breast cancer patients, before and after chemotherapy.
In a PET treatment, patients are injected with small amounts of radiopharmaceuticals, which create images of tissue chemical changes that could be early warning signs of cancer. Uses for the radiopharmaceuticals include spotting changes in glucose metabolism, monitoring the effectiveness of drug therapy during cancer treatments, and tracking whether tumors are diverting new blood vessels to sustain their growth.
The research is being overseen at the Hammersmith Hospital
in London by David Brooks, chief medical officer of GE Imanet, which handles GE Healthcare's international network of imaging research centers.
GE Healthcare is a division of General Electric. The company manufactures medical imaging technology at its Waukesha headquarters, GE Healthcare Technologies, and its Milwaukee location, GE Healthcare Information Technologies.
Michael Rosen: Midwest retains dominant role in 2005 world medical device market
GE announces first installation of Discovery VCT
GE, St. Jude to collaborate on visualization technology